Affymetrix reiterated its commitment to deliver on three main business priorities to reinvigorate its gene-expression and genotyping businesses after a year of sluggish sales attributed to declining demand for its array products amid weak pharma spending.

According to CEO Kevin King, Affy's three-pronged strategy includes targeting downstream genomicanalysis markets with the new products gained through its acquisitions of Panomics and True Materials last year; rolling out new genotyping assays on its GeneTitan array platform, and consolidating its manufacturing facilities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Related Articles

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.